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Abstract 
Background: In this phase 1 clinical trial, healthy adult, malaria-naïve subjects were immunized with radiation-atten-
uated Plasmodium falciparum sporozoites (PfRAS) by mosquito bite and then underwent controlled human malaria 
infection (CHMI). The PfRAS model for immunization against malaria had previously induced >90 % sterile protection 
against homologous CHMI. This study was to further explore the safety, tolerability and protective efficacy of the 
PfRAS model and to provide biological specimens to characterize protective immune responses and identify protec-
tive antigens in support of malaria vaccine development.
Methods: Fifty-seven subjects were screened, 41 enrolled and 30 received at least one immunization. The true-
immunized subjects received PfRAS via mosquito bite and the mock-immunized subjects received mosquito bites 
from irradiated uninfected mosquitoes. Sera and peripheral blood mononuclear cells (PBMCs) were collected before 
and after PfRAS immunizations.
Results: Immunization with PfRAS was generally safe and well tolerated, and repeated immunization via mosquito 
bite did not appear to increase the risk or severity of AEs. Local adverse events (AEs) of true-immunized and mock-
immunized groups consisted of erythaema, papules, swelling, and induration and were consistent with reactions from 
mosquito bites seen in nature. Two subjects, one true- and one mock-immunized, developed large local reactions 
that completely resolved, were likely a result of mosquito salivary antigens, and were withdrawn from further partici-
pation as a safety precaution. Systemic AEs were generally rare and mild, consisting of headache, myalgia, nausea, 
and low-grade fevers. Two true-immunized subjects experienced fever, malaise, myalgia, nausea, and rigours approxi-
mately 16 h after immunization. These symptoms likely resulted from pre-formed antibodies interacting with mos-
quito salivary antigens. Ten subjects immunized with PfRAS underwent CHMI and five subjects (50 %) were sterilely 
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Background
Despite significant reductions in the prevalence of 
malaria during the last 15  years [1], emerging drug and 
insecticide resistance and the significant ongoing bur-
den of morbidity and mortality emphasize the need for 
an effective malaria vaccine. Such a vaccine is possible, 
as radiation-attenuated sporozoites (RAS) administered 
intravenously (IV) to mice [2] or by mosquito bite [3] to 
mice and non-human primates [4] induce almost com-
plete sterile protection. During the 1970s, 1980s and early 
1990s a series of human studies using Plasmodium falci-
parum RAS (PfRAS) delivered by bite of irradiated mos-
quitoes similarly induced nearly 100 % sterile protection 
as long as sufficient numbers of immunizing bites were 
administered [5–9]; since parasitaemia was completely 
prevented in these volunteers, all clinical manifestations 
of malaria were avoided. Beginning in 1989, additional 
human subjects were immunized with PfRAS and the 
immunological outcomes were extensively published 
[10–14]. Ten out of ten subjects (100  %) given greater 
than 1000 bites were fully protected against controlled 
human malaria infection (CHMI) conducted less than 
10  weeks after immunization (one undergoing CHMI 
at 10  weeks was not protected), six of six (100  %) were 
protected on repeat CHMI within 10  weeks of primary 
CHMI, and five of six (83  %) were protected on repeat 
CHMI within 23–42  weeks of primary CHMI, indicat-
ing that protection was durable for at least 10  months 
[15]. These studies also showed that protection extended 
to heterologous strain parasites (parasites genetically 
and antigenically different from the immunizing strain), 
as several subjects immunized with an African malaria 
strain (NF54) were protected against a parasite cloned 
from a Brazilian isolate (7G8) [15].
Although these studies provided proof of concept that 
sporozoites could induce high-level immunity, as a vac-
cine for human use, PfRAS immunization was deemed 
impractical for many decades due to the complexity of 
administering a vaccine via mosquito bite, the require-
ment for a secure insectary and a laboratory for main-
taining P. falciparum in culture, and the perceived need 
for five or more immunization sessions to achieve a 
sufficient number of bites. Recently, it has been dem-
onstrated that the Sanaria PfSPZ vaccine, composed of 
aseptic, purified, cryopreserved, PfRAS is safe, well-tol-
erated, easily administered by syringe using a variety of 
routes, and can induce 100 % protective efficacy against 
CHMI when administered intravenously [16, 17]. PfRAS 
immunization by mosquito bites or by syringe therefore 
serves as a model for high-grade, cross-strain protec-
tive immunity in animals and humans, creating a strong 
rationale to develop a sub-unit vaccine approach that 
might provide equivalent protection, if the protective 
immune mechanisms and targeted antigens could be 
identified.
The sterile immunity induced by RAS appears to be 
mediated primarily by CD8+ and CD4+ T cell-depend-
ent mechanisms targeting antigens expressed by sporo-
zoites and liver-stage parasites [11, 13, 14, 18]. Responses 
to a liver-stage antigen were also identified in one study 
[14]. In rhesus monkeys, and in most murine stud-
ies, CD8+  cells were required for protection [19–22]. 
Murine studies suggest that inflammatory cytokines such 
as interferon-gamma (IFN-γ) induce the nitric oxide 
pathway in hepatocytes to kill liver-stage parasites [23], 
or that the infected hepatocytes are destroyed by direct 
cytotoxic activity [24]. Sporozoite-neutralizing anti-
bodies likely contribute significantly to protection [10, 
25], particularly when CHMI is conducted soon after 
immunization.
Antibodies also appear to contribute to protection. 
Studies in mice and humans show that immunization 
with RAS induces sporozoite-neutralizing antibod-
ies [10, 16] that recognize the circumsporozoite protein 
(CSP), an abundant protein forming the surface coat of 
the sporozoite [4]. This finding led to the cloning of P. 
falciparum CSP [26, 27] and the formulation of several 
CSP-based sub-unit vaccines designed to induce pro-
tective antibodies [28, 29]. Although efficacy was low, 
subsequent development of CSP using a particle-based 
approach has led to the currently most advanced malaria 
sub-unit vaccine, RTS,S/AS01, that elicits 30  % protec-
tion in young children [30] primarily mediated by anti-
CSP antibodies and CD4+ T cells [31, 32]. When tested 
protected and there was a significant delay to parasitaemia in the other five subjects. All ten subjects developed 
humoral immune responses to whole sporozoites and to the circumsporozoite protein prior to CHMI, although the 
differences between protected and non-protected subjects were not statistically significant for this small sample size.
Conclusions: The protective efficacy of this clinical trial (50 %) was notably less than previously reported (>90 %). This 
may be related to differences in host genetics or the inherent variability in mosquito biting behavior and numbers 
of sporozoites injected. Differences in trial procedures, such as the use of leukapheresis prior to CHMI and of a longer 
interval between the final immunization and CHMI in these subjects compared to earlier trials, may also have reduced 
protective efficacy. This trial has been retrospectively registered at ISRCTN ID 17372582, May 31, 2016.
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in the field, RTS,S does not induce sterile protection, but 
rather reduces the frequency of clinical malaria. The lack 
of CD8+ T cell responses may be one reason. In addition 
to protein-based sub-unit vaccines, gene-based vaccines 
have shown promise, particularly in heterologous prime-
boost regimens [33, 34], although efficacy is still well 
below that of RAS. The partial efficacy of these first gen-
eration sub-unit vaccines suggests that a better under-
standing of RAS-induced protective mechanisms may 
provide a rationale to develop alternative or improved 
sub-unit strategies using newly discovered antigens or 
more potently inducing cell-mediated immunity.
To address this objective, a new human trial using P. 
falciparum (strain NF54) RAS was conducted from 1999 
to 2002 with the primary goal to obtain samples for inves-
tigation of protective immune mechanisms and antigen 
discovery. Fifteen healthy adult subjects were immu-
nized five to six times by mosquito bite at intervals of 
5–7 weeks (with the exact timing based on the availability 
of sufficient numbers of PfRAS-infected mosquitoes) to 
achieve a total of at least 1000 bites of irradiated, infected 
Anopheles stephensi mosquitoes, and seven received a 
similar number of non-infectious bites (mock-immu-
nized controls) to control for the effects of mosquito sali-
vary antigens injected during the mosquito bites. Ten of 
the true-immunized subjects and five non-immunized 
infectivity controls underwent CHMI with homologous 
strain (NF54) infectious sporozoites administered by five 
mosquito bites, to assess protection and to investigate 
possible correlation between the CHMI outcome and 
immune responses. Sera, plasma and peripheral blood 
mononuclear cells (PBMC), using leukapheresis to obtain 
large numbers of lymphocytes, were collected from all 
subjects. These samples have already been used to inves-
tigate the antigenic targets induced by PfRAS [35–40], 
underscoring the usefulness of these studies for vaccine 
development. Here, the safety, tolerability, protection, 
and humoral response data collected during this clinical 
trial are reported. The trial increases from 14 to 24 the 
total number of subjects receiving more than 1000 infec-
tious bites and undergoing CHMI within the published 
literature.
Methods
Objectives
The objectives of this study were to determine whether 
a minimum of 1000 bites of irradiated P. falciparum-
infected mosquitoes was safe and well tolerated and 
would elicit protection in up to 100  % immunized sub-
jects as previously proposed [15], and to provide immune 
samples to investigate correlates of protection, includ-
ing both the immunological responses and the targeted 
P. falciparum antigens. Research subjects were enrolled 
into three groups: (1) ‘true-immunized’ subjects who 
were immunized by the bites of An. stephensi mosquitoes 
infected with irradiated sporozoites, followed by CHMI; 
(2) ‘mock-immunized’ subjects who were immunized by 
the bites of uninfected mosquitoes, but not exposed to 
CHMI; and, (3) infectivity controls who were not immu-
nized but were exposed to CHMI at the same time as the 
true-immunized subjects in order to prove the viability of 
the CHMI.
Ethics
The study was conducted at the Naval Medical Research 
Center (NMRC) Clinical Trials Center between 1999 and 
2002. At the time of these studies, the Food and Drug 
Administration (FDA) did not require the administration 
of infectious mosquito bites to be conducted under an 
Investigational New Drug (IND) allowance. This trial was 
retrospectively registered at ISRCTN ID 17372582. The 
study protocol was reviewed and approved by the NMRC 
Institutional Review Board in compliance with all federal 
regulations governing the protection of human subjects. 
Walter Reed Army Institute of Research (WRAIR) holds 
a Federal-wide Assurance from the Office of Human 
Research Protections (OHRP) under the Department of 
Health and Human Services as does NMRC. NMRC also 
holds a Department of Defense/Department of the Navy 
Federal-wide Assurance for human subject protections. 
All key personnel were certified as having completed 
mandatory human research ethics education curricula 
and training under the direction of the WRAIR Institu-
tional Research Board or the NMRC Office of Research 
Administration (ORA) and Human Subjects Protections 
Program (HSPP). All potential study subjects provided 
written, informed consent before screening and enrol-
ment and had to pass an assessment of understanding.
Study population
Healthy, malaria-naïve, non-pregnant adults between the 
ages of 18 and 50 were included in this study. Malaria-
naïve status was confirmed by travel history, medical his-
tory and P. falciparum CSP ELISA screening.
True and mock immunization procedures
The infected mosquito batches used for true-immuni-
zation were infected 14–21  days prior to human biting 
with the chloroquine-sensitive NF54 strain of P. falci-
parum by membrane feeding on in vitro blood cultures 
at the Biological Research Institute, Rockville, MD, 
USA. Monitoring for salivary gland infections was con-
ducted by hand dissection of a representative sample 
from the batch, grading infection rates as gland scores: 
1–10 sporozoites  =  gland score 1; 11–100 sporozo-
ites = gland score 2; 101–1000 sporozoites = gland score 
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3; and  >1000 =  gland score 4. A gland score of two or 
higher was used as the cut-off to count a mosquito as 
‘infected’, although those with ten or fewer sporozoites on 
dissection could still be infectious and inject sporozoites 
during feeding. The morning of an immunization pro-
cedure, mosquito batches with 70 % or more of mosqui-
toes showing gland score 2 or higher were transported to 
NMRC/WRAIR, Silver Spring, MD, USA and subjected 
to 15,000 cGy using a Model 109-68 Cobalt60 irradiator.
Both true- and mock-immunizations were conducted 
in the secure WRAIR/NMRC insectary by placing two 
cylindrical cardboard containers with mosquito net-
ting at one end, each holding approximately 200 mos-
quitoes, in contact with the volar surface of one forearm 
for 5  min, followed 2  min later by a second 5-min feed 
with the same mosquitoes at the same sites. Consistent 
with previous experience, approximately 70 % of the 400 
mosquitoes in the two containers (200 × 2) took a blood 
meal. After the two 5-min feeding sessions, a sample of 
the engorged mosquitoes was hand-dissected to calculate 
infectivity rates. The total number of engorged mosqui-
toes was multiplied by the per cent of mosquitoes with 
mean gland grade at least 2 to estimate the dose of infec-
tious bites. The goal for the full immunization series was 
for the true-immunized group to receive a minimum of 
1000 irradiated infectious mosquito bites before CHMI. 
In practice, this required five to six immunization ses-
sions. Similarly, the goal for the mock-immunized group 
was to receive a minimum of 1000 non-infectious mos-
quito bites, with the number of bites from each immu-
nization session calculated in this latter case as the 
number of engorged mosquitoes. Mosquitoes used for 
mock immunization were raised, handled and irradi-
ated in the same fashion as those for true immunization 
except they were not fed on P. falciparum blood cultures. 
Both true- and mock-immunized subjects were observed 
on site for at least 30 min after each immunization.
Controlled human malaria infection (CHMI)
Five non-irradiated mosquitoes, infected with the same 
NF54 strain of P. falciparum used for immunization were 
allowed to feed once for 5  min on the subjects. All fed 
mosquitoes were dissected to determine the infectiv-
ity rate. Replacement mosquitoes for those of the initial 
five not feeding or feeding but found on dissection to 
have gland grades of 1 or less (ten sporozoites or fewer) 
were then allowed to feed and this process was repeated 
until five infectious bites had been achieved. Beginning 
7 days after CHMI, subjects were assembled each night 
in a regional hotel for clinical monitoring by study staff. 
Each morning, thick blood smears were made for micro-
scopic examination, and sufficient passes over the slide 
were made using the high-power objective, such that 
approximately 40 µL of blood were examined. The pres-
ence of two parasites was required for a positive diagno-
sis, leading to immediate anti-malarial treatment with 
chloroquine phosphate. The treatment regimen was 
directly observed and included 1000  mg chloroquine 
phosphate salt (600  mg chloroquine phosphate base) 
immediately, 500 mg salt (300 mg base) at 6 h and again 
at 24 and 48  h. Subjects who were positive were moni-
tored daily by symptom checks and blood smears until 
three consecutive negative smears were documented and 
subjects remaining negative were similarly monitored 
until day 21 post CHMI, then approximately every other 
day until day 28. Those remaining negative on day 28 
were considered fully protected.
Adverse events (AEs)
Subjects were examined by physical examination and ver-
bal questioning for local adverse events at 24, 48 and 72 h 
and at 1 and 2 weeks after each immunization. Although 
specific systemic symptoms were not actively solicited, 
subjects were asked in open-ended fashion to describe 
any systemic symptoms to the evaluating clinician, and 
these were recorded.
AE grading
Local AEs were subjectively graded as follows:
Mild: Minimally apparent symptoms noticed by the study 
subject (pain, tenderness, pruritus) or signs noticed by 
the examiner (erythaema, induration, swelling, lymphad-
enitis) but not requiring treatment.
Moderate: Symptoms or signs quite evident to the study 
subject (pain, tenderness, pruritus) or the examiner 
(erythaema, induration, swelling, lymphadenitis), poten-
tially interfering with the activities of daily living (ADLs); 
treatment offered (i.e., study subject provided with topi-
cal corticosteroid cream to apply as needed).
Severe: Clinically significant findings interfering with daily 
activities; study subject requested or examiner recom-
mended immediate local and/or systemic treatment with 
topical corticosteroids and/or oral antihistamines/corti-
costeroids/non-steroidal anti-inflammatory drugs.
Systemic AEs were subjectively graded as follows:
Mild: No treatment required; ADLs not compromised 
(subject able to work, or attend school).
Moderate: Outpatient treatment required, ADLs only 
minimally compromised (subject able to work, or attend 
school). Severe: Outpatient treatment required, ADLs 
compromised (subject not able to work or attend school). 
Serious: AEs resulting in death; AEs that were life-threat-
ening, meaning that failure to intervene could result in 
hospitalization or death (example: bronchospasm requir-
ing parenteral medication in the emergency room, or 
grand mal seizure evaluated in the emergency room but 
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not resulting in hospitalization); AEs leading to or pro-
longing inpatient hospitalization; AEs resulting in per-
sistent or significant disability or incapacity, including 
addiction; congenital anomaly or birth defect in an infant 
conceived by a subject.
Laboratory tests
Screening clinical laboratory tests were initially collected 
to determine enrolment eligibility. These tests included 
a complete blood count (CBC) and screens for hepatitis 
B virus, hepatitis C virus and human immunodeficiency 
virus. Once a study subject was enrolled but prior to 
immunization, additional sampling was performed by 
withdrawal of whole blood and by leukapheresis, to pro-
vide pre-immunization serum, PBMCs and plasma for 
banking. Additional blood collections were performed 
at various time points throughout the trial for banking 
serum, PBMCs and plasma. Leukapheresis was repeated 
halfway through the immunization series in some sub-
jects and after the final immunization/prior to CHMI in 
all subjects that underwent CHMI. There was no system-
atic collection of safety laboratory data beyond screening 
for enrolment and a CBC prior to each leukapheresis. 
Additional samples for safety laboratory tests were col-
lected only in study subjects as clinically indicated.
Immunofluorescence antibody assay (IFA) using 
sporozoites
Serum antibody levels were assessed by IFA against air-
dried P. falciparum 3D7 strain sporozoites; 3D7 is a clone 
of NF54 obtained by limiting dilution [41]. To prepare 
the IFA slides, infected mosquitoes were suspended in 
3  % bovine serum albumin (BSA) at a concentration of 
106 sporozoites per mL. An aliquot of 10 µL containing 
104 sporozoites was delivered into each well of the anti-
gen slide. The antigen slides were allowed to air dry at 
room temperature and were kept at −70  °C until used. 
20 µL of a twofold serial dilution of test or control serum 
in PBS containing 2 % BSA was added to each well of the 
antigen slides. The slides were incubated for 1 h at 37 °C, 
washed three times in PBS, 5 min each wash. Each well 
was incubated for 30 min at 37  °C with 20 µL of a 1:50 
dilution of FITC-labelled goat anti-human IgG (H+L) 
(Kirkegaard and Perry). The slides were washed again, 
mounted in a Vectashield mounting medium (Vector 
Laboratories, Inc.) and examined under an Olympus UV 
microscope and end-point titers were determined as the 
last dilution above the background that fluorescent para-
sites were observed.
Enzyme‑linked immunosorbent assay (ELISA)
The P. falciparum recombinant proteins used in the 
ELISA assays, CSP, SSP2/TRAP, EXP1, and LSA1 have 
been previously described [42–44]. Stock solutions of 
P. falciparum recombinant proteins were diluted in 
phosphate buffered saline, pH 7.2, to the optimal con-
centration of each (0.5  µg/mL for CSP, 1.0  µg/mL for 
SSP2/TRAP, 2.0 µg/mL for EXP1, 4.0 µg/mL for LSA1) 
as previously described [45, 46]. The ELISA titre was 
defined as the calculated serum dilution yielding an 
optical density of 0.5 in the assay. Samples were con-
sidered positive if the titre of the sample post-immu-
nization was greater than the titre plus two standard 
deviations of the sample pre-immunization and greater 
than twofold higher than the corresponding pre-immu-
nization sample.
Sample size and statistical assessment
The primary objective of the study was to collect PBMCs, 
sera and plasma before and after PfRAS immunization, 
and then to characterize protective immune responses 
and identify protective antigens for malaria vaccine 
development by comparing protected and non-protected 
research subjects. The number of study subjects was con-
strained by the capacity to generate infected mosquitoes.
The log rank test was used to compare time to parasi-
taemia between infectivity control and non-protected 
immunized subjects. The Mann–Whitney U test was 
used to compare the interval between protected and 
unprotected subjects and the interval between leukapher-
esis and CHMI for protected and non-protected subjects. 
The repeated measure analysis of variance was used to 
compare the means of the IFA titres between protected 
and non-protected subjects. The IFA titres were log10 
transformed prior to the analysis. The repeated measure 
analysis of variance was also used to compare the means 
of the ELISA titres between protected and non-protected 
subjects. Statistical significance was defined as a two-
tailed P ≤ 0.05.
Results
Study flow
The participant flow is shown in Fig.  1. Recruitment 
took place at the NMRC Clinical Trials Center between 
September 1999 and August 2002. A total of 57 sub-
jects were assessed for eligibility and 16 were excluded. 
The remaining 41 subjects, who met all screening crite-
ria, were enrolled and assigned to the true-immunized 
(22 subjects), mock-immunized (13 subjects) and infec-
tivity control (six subjects) groups. Thirty of these 41 
enrolled subjects initiated the immunization regimens 
(17 true-immunized, 13 mock-immunized), and three 
true-immunized underwent CHMI in 1999–2000 and 
seven true-immunized underwent CHMI in 2001–
2002. Demographics of the study subjects are shown in 
Table 1. Immunization was performed when PfRAS were 
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Fig. 1 Flow diagram of immunized and control subjects. 41 subjects met all eligibility criteria and were assigned to the true-immunization group 
(n = 22), mock-immunization group (n = 13) and infectivity controls (n = 5). True-immunized group contained subjects enrolled in 1999–2000 and 
2001–2002
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available resulting in varying immunization schedules for 
the subjects, and the CHMI was performed in two groups 
as described below.
Immunization procedures
True-immunized group: Five subjects enrolled in 1999–
2000 completed six immunizations and three subjects 
received CHMI in the first cohort in 2000. Ten of 14 
subjects enrolled in 2001–2002 completed five immu-
nizations, and seven of these ten subjects completed six 
immunizations; six subjects who completed six immu-
nizations and one subject who completed five immu-
nizations (total seven subjects) received CHMI in the 
second cohort in 2002 (Fig. 1). Three of the ten subjects 
who received five immunizations withdrew after the fifth 
immunization (one for personal reasons; one because of a 
family emergency, and one due to relocation outside the 
geographic area). One of the seven subjects who com-
pleted six immunizations did not receive CHMI because 
of an unrelated illness on the day of CHMI. In addition, 
one subject was withdrawn after the first immunization 
due to illness, and one subject was withdrawn after the 
second immunization (see “AEs” section).
The immunization regimens for the ten subjects who 
underwent CHMI are shown in Fig.  2, and summarized 
in Table 2. Although the numbers of subjects in these two 
groups were too small to reliably distinguish statistically, 
the ranges of numbers of bites, numbers of immunizations, 
intervals between immunization, intervals before CHMI, 
and salivary sporozoite gland score appeared similar, sug-
gesting that these parameters were highly similar between 
the two groups. When combined, the median number of 
infectious bites per immunization session was 214 (range 
175–260), the median total number of infectious bites was 
1247 (range 1005–1561), and the median interval between 
immunizations was 43 days (range 35–48 days).
Mock-immunized group: In parallel to these true immuni-
zations, seven subjects received at least five mock immu-
nizations over 175–239 days (Fig. 1) receiving a total of 
1210–1890 (median 1636) irradiated non-infectious mos-
quito bites. None of these subjects underwent CHMI.
Additional true-immunized subjects: Four of the ten sub-
jects who underwent CHMI, including three from the 
1999–2000 group and one from the 2001–2002 group, and 
one subject enrolled in 1999–2000 who was immunized 
but did not undergo CHMI, received further RAS immu-
nizations (see Additional file 1). One of the four subjects 
immunized and undergoing CHMI with the 1999–2000 
cohort, subject number 20, was not protected, was immu-
nized with six additional immunizations, and joined the 
second cohort CHMI, and was protected; he received one 
further immunization following the second CHMI, for a 
total of 13 immunizations (see Additional file 1). The sev-
eral immunizations described here that were not followed 
by CHMI contributed to the safety data presented below.
Safety and tolerability
Local adverse events (AEs)
During the interval between study completion and pub-
lication, these records were securely maintained in a 
storage facility that flooded; this incident resulted in the 
loss of several original records. Original subject records, 
source documents and case report forms (CRFs) were 
available for 19 of 30 immunized (11 true- and eight 
mock-immunized) subjects that received immunization 
1, for 15 subjects for immunizations 2–5 (ten true- and 
five mock-immunized), and ten subjects who received 
immunization 6 (seven true- and three mock-immu-
nized subjects). The frequency of AEs during immuniza-
tions 1–6 is shown in Fig. 3. The remaining 11 subjects 
with missing source data comprised seven subjects who 
received at least one true-immunization and four who 
received at least one mock-immunization. However, AE 
summary data from these 11 subjects were available in 
reports submitted to the IRB during the conduct of the 
trial. Comparing these summary reports on 30 subjects 
to the available original source documentation on 19 
Table 1 Study subjects demographics
Seventeen subjects were enrolled into the true-immunized group that received 
bites of PfRAS mosquitoes; five subjects were enrolled in 1999–2000 and 12 
subjects were enrolled in 2001–2002. Thirteen subjects were enrolled into the 
mock-immunized group that received bites of uninfected mosquitoes, and six 
subjects enrolled as infectivity controls of whom five received CHMI
True‑immunized Mock‑ 
immunized
Infectivity 
controls
1999–2000 2001–2002
Gender
 Male 5 12 11 4
 Female 0 0 2 1
Total 5 12 13 5
Age 
(mean + SD)
42 ± 10 34 ± 8 34 ± 7 36 ± 8
Race/ethnicity
 African–
American
0 3 1 2
 Caucasian 5 8 7 2
 Hispanic 0 0 0 0
 Not known 0 1 5 1
Total: true-
immunized
17
Total: mock-
immunized
13
Total: infectivity 
controls
5
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subjects indicated that no severe or serious AEs were 
omitted from the missing data set. While mild and mod-
erate AEs could not be enumerated individually for the 
11 subjects with missing charts, the findings of mild and 
moderate AEs on the 19 subjects with source documen-
tation were representative of the total mild and moderate 
AEs as presented in the summary reports.
All immunization safety data from the available source 
documents of 19 subjects were analysed and the mild to 
moderate AEs, after each immunization, are shown in 
Fig. 3. In general, most AEs occurred within the first 48 h 
and resolved in seven to 14 days. Subjects noted mild dis-
comfort during mosquito feeding and experienced mild 
to moderate local reactogenicity afterwards. Immediately 
after each 10-min biting session, the skin exhibited mild 
to moderate erythaema restricted to the circular area in 
contact with the cylindrical mosquito container, with 
or without associated mild to moderate induration and 
swelling. In many subjects, small erythaematous papules 
demarcated the precise sites of mosquito probing; these 
were also confined to the region where the mosquito con-
tainer was applied. In some individuals, the papules coa-
lesced into an elevated, confluent, erythaematous plaque. 
These plaques as well as other signs and symptoms typi-
cally resolved within 24–72 h. Pain and tenderness repre-
sented only a small proportion of the reported AEs while 
pruritus and erythaema were more common. Because 
subjects received varying numbers of immunizations in 
sessions 1–6, the numbers of AEs/subject are shown, and 
were similar after each immunization (true-immunized 
geometric mean 3.2 AEs per subject per immunization, 
range 3.0 to 3.6; mock-immunized geometric mean 3.4 
AEs per subject per immunization, range 2.8–4.0).
In two subjects, local reactions extended significantly 
beyond the area of skin to which the container of feeding 
mosquitoes had been applied, and were graded as severe. 
These occurred following the second immunization in 
two subjects, one true-immunized (subject #29) and one 
Fig. 2 Immunization regimes for the ten subjects who underwent CHMI. Red boxes indicate PfRAS immunization, blue boxes represent CHMI and 
the numbers indicate the study day for that subject (day 0 was the day of the first immunization). Subjects 20, 21 and 30 were in the first cohort for 
CHMI, and the rest were in the second cohort for CHMI
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Table 2 Summary of immunizations in this study subjects who were true-immunized in 1999–2000) and 2000–2002
The median and range of the immunizations are shown of all subjects in the two groups (1999–2000 and 2000–2001) who underwent CHMI. Sample sizes were too 
small to reliably do a statistical comparison
a Gland score as defined in “Methods” section, salivary infection rates were defined as gland scores: 1–10 sporozoites = gland score 1; 11–100 sporozoites = gland 
score 2; 101–1000 sporozoites = gland score 3; and >1000 = gland score 4
Group
1999–2000 2000–2001
Number of subjects 3 7
Median Range Median Range
Infected bites in the first immunization 148 138–334 227 178–252
Total infected bites 1408 1322–1561 1161 1005–1561
Median infected bites per immunization 235 220–260 212 175–260
Number of immunizations 6 6–6 6 5–6
Duration of immunizations (days) 239 231–239 183 175–211
Median immunization interval (days) 37 21–91 29.5 15–100
Interval before CHMI (days) 24 24–24 35.5 15–42
Median gland grade scorea during immunization 3.8 3.8–3.9 3.4 3.2–3.6
Median gland grade score during CHMI 2.4 2.4–2.8 2.8 2.4–3.2
Fig. 3 Frequency of true- and mock-immunized subjects experiencing local adverse events after each immunization 1–6. Number of local AEs 
(mild/moderate) experienced by each subject after true- and mock-immunizations 1–6. The numbers at the top of the graphs represent the number 
of individuals immunized at each immunization. The numbers at the  top of each column represent the number of AEs/subject. The number of AEs 
per subject per immunization for each group were very similar in the true-immunized and mock-immunized subjects. All AEs were mild or moder-
ate in severity except for one severe AE (swelling) in one true- and one-mock immunized subject at immunization 2 denoted by asterisks
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mock-immunized (subject #35), who developed “large 
local reactions” consisting of swelling that extended 
from the wrist to the elbow (see asterisk in Fig.  3). 
Interestingly, the mock-immunized subject had shown 
erythaematous lymphangitic streaks on the volar aspect 
of the arm from the bite site to the axillae after the first 
immunization. The clinical investigators obtained a con-
sultation from a clinical immunologist and allergist who 
advised that the reactions were likely due to IgE-medi-
ated histamine responses following the introduction of 
mosquito salivary antigens. In both cases, the large local 
reactions resolved uneventfully over 1or 2  days without 
sequelae. Both subjects were withdrawn from further 
participation and were not re-immunized. One was avail-
able for follow-up and reports that during the subsequent 
10  years, mosquito bites often result in an immediate 
wheal and flare reaction (1 cm in diameter) with itching 
and irritation, resolving over 10 min, but no recurrence 
of the large local reaction.
Systemic adverse events
Systemic AE data were likewise available from the source 
documents of the same 19 immunized (11 true- and eight 
mock-immunized) study subjects for which local AEs 
are reported, and are provided in Fig. 4. In general, most 
systemic AEs occurred within the first 48 h and resolved 
within 7 days. Among true-immunized subjects, systemic 
AEs were generally characterized as mild and consisted 
of headache, myalgia, nausea, and low-grade fever. One 
subject reported a cough of moderate intensity following 
immunization, deemed unlikely related to immunization. 
In contrast, systemic AEs were absent after mock-immu-
nization, except one mild AE (headache) in one subject 
after the first mock-immunization (Fig. 4). This difference 
suggests that P. falciparum sporozoites may elicit sys-
temic AEs, although of lower frequency than local AEs.
Two true-immunized study subjects, number 20 and 
number 66, experienced unexpected systemic reactions 
that were unique to these subjects and are not there-
fore included among the AEs in Fig.  4. These individu-
als reported a range of symptoms ranging from mild 
to severe that, due to timing and similarity, appeared 
likely related to immunization. These systemic AEs are 
reported in Additional file 2.
Clinical laboratory adverse events
Clinical laboratory tests were performed on all subjects at 
screening, but thereafter only on a case-by-case basis in 
Fig. 4 Frequency of true- and mock-immunized subjects experiencing systemic adverse events after each immunization 1–6. Number of local AEs 
(mild/moderate) experienced by each subject after true- and mock-immunizations 1–6. The numbers at the top of the graphs represent the number 
of individuals immunized at each immunization. The numbers at the top of each column represent the number of AEs/subject. The timing of each 
immunization is shown in Fig. 2
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accordance with the clinical judgment of an investigator 
evaluating a complaint by a study subject. Twenty-two 
tests were conducted on 19 subjects at various time-
points during the immunization phase of the trial (prior 
to CHMI). Due to the non-systematic collection of clini-
cal laboratory samples, it is uncertain when most labora-
tory AEs occurred; however, the laboratory AEs resolved 
prior to receiving additional immunizations. For one sub-
ject, one post-immunization aspartate aminotransferase 
(AST) and alanine aminotransferase ALT) were slightly 
elevated, 67 (normal 17–49) and 62 (7–59), respectively; 
several CBC indices were abnormal in 11 subjects with 
the most out-of-range values a haemoglobin (HGB) of 
12.5 (normal 14–18), haematocrit test (HCT) of 36.6 
(normal 42–52), white blood cell (WBC) of 3.7 (normal 
4.0–11.0), and red blood cell (RBC) of 4.04 (normal 4.7–
6.1)]. These were all grade 1 excursions in severity based 
on the FDA’s toxicity grading scale for healthy adult and 
adolescent subjects enrolled in preventive vaccine clinical 
trials [47].
Protective efficacy and time to parasitaemia
The three subjects enrolled in 1999–2000 received CHMI 
as one group, and seven subjects enrolled later received 
CHMI as the second group. Because the immunization 
schedule for many subjects was individualized (Fig.  2), 
the timing of CHMI varied from 15 to 42 days after the 
last immunization (Fig. 2). Five of ten subjects were ster-
ilely protected after CHMI (2/3 in the first CHMI, 3/7 in 
the second CHMI). The time to parasitaemia was delayed 
in the five unprotected subjects compared to infectiv-
ity controls (13  vs 10  days, P  =  0.03) (Fig.  5). Overall, 
the time to parasitaemia observed in the Kaplan–Meier 
plot in the true-immunized and infectivity controls was 
statistically significantly different (P  <  0.0001, log rank 
test). The mock-immunized subjects did not undergo 
CHMI.
Comparison of immunization procedures with prior 
studies: association between delayed CHMI and loss 
of protection
The 50  % protection in this study is lower than that in 
previous trials [15]. The immunization procedures for 
ten subjects previously immunized in 1989–1999 at 
NMRC are shown in Fig. 6. Ten subjects received five to 
ten immunizations over 99–547 days, receiving a total of 
1001–1163 (median 1070) PfRAS bites, and underwent 
CHMI 14–71  days later with five infectivity controls. 
Nine of these ten subjects were sterilely protected. The 
median number of infectious bites per immunization 
session was 125 (range 109–210) and the median of the 
estimated grades of salivary gland scores was 3.2 (range 
3.0–3.7).
The immunization procedures for the current study 
(Table  2) are combined and compared to those for the 
1989–99 study in Table  3. The 1989–99 volunteers 
received significantly (P =  <0.05) fewer total number of 
infectious bites, fewer number of infectious bites in the 
first immunization, fewer bites per session, more immuni-
zation sessions, longer duration of immunization, shorter 
interval between last immunization and CHMI, decreased 
median gland score during immunization, and increased 
gland score during CHMI, but the median interval 
between immunizations was similar (Table  3). For both 
studies, subjects were predominantly protected when 
CHMI was less than 28  days, and were predominantly 
not protected more than 28 days, after the last immuni-
zation (Fig.  7). The times to CHMI between protected 
and non-protected volunteers were not statistically dif-
ferent in the current study. However, when the data from 
all 20 research subjects (current study and prior study) 
were combined, the median interval between last immu-
nization and CHMI was significantly different between 
protected and unprotected subjects (20.0 vs 36.0  days; 
P = 0.01, Mann–Whitney U test; Fig. 7), suggesting that 
PfRAS induced protective immunity may have been 
short-lived.
Effect of leukapheresis and protection
Leukapheresis was performed in the 1999–2002 study but 
not the 1989–1999 study. Leukapheresis may temporar-
ily remove a significant proportion of circulating PBMC 
[48] that might affect T cell-dependent protection. Liver-
resident T cells are thought to mediate protection [49], 
and the effects of leukapheresis on this population are 
not known. However, there was no association between 
the timing of leukapheresis since the subjects with the 
Fig. 5 Development of parasitaemia in the immunized and infectiv-
ity control subjects. Parasitaemia-free survival curves (Kaplan–Meier) 
for immunized subjects and infectivity controls based on microscopic 
examination of peripheral blood smears. P < 0.0001 (Log rank test)
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longest interval were not protected, while those with the 
shortest interval were protected (P = 0.40, Mann–Whit-
ney U test) (see Additional file 3).
Repeat CHMI
Subject number 20, as previously discussed under AEs 
following immunization #13, was the only subject to 
undergo a repeat CHMI in this study (see Additional 
file  1). He received six true-immunizations for a total 
of 1322 infectious bites (estimated) as part of the first 
CHMI cohort. He underwent CHMI and was not pro-
tected. Subsequently, his enrolment continued and he 
received an additional six true-immunizations as part of 
the second CHMI cohort for a total of 12 immunizations. 
He underwent a secondary CHMI as part of Cohort 2 
and was protected. He later received a 13th immuniza-
tion that was associated with the systemic AE, which is 
also described in Additional file 2.
Humoral responses
Peak sporozoite IFA and CSP ELISA titres generally 
occurred between the second and fourth immunizations 
(Fig. 8) but the difference in geometric mean titres between 
protected and non-protected subjects was not statistically 
significant. Low titres (<1:1000) of anti-TRAP antibodies 
were detected in 8/10 subjects but there were no detectable 
antibodies to LSA1, Exp1 or LSA3 in any subject.
Discussion
Immunization with RAS by mosquito bite established the 
original gold standard for protection against falciparum 
malaria in the early 1970s, and earlier studies of PfRAS 
showed up to 93  % efficacy (13/14 subjects) [15]. These 
studies established that a malaria vaccine was feasible, 
and that sporozoite-specific antibodies and CD4+  and 
CD8+ T cells were induced by this form of immunization. 
Murine and simian studies established that CD8+  cells 
Fig. 6 Immunization regimes for ten subjects who underwent CHMI in a prior study conducted 1989–1999. Ten subjects were immunized by bite 
of PfRAS during 1989–1999 [15] and received CHMI. The days of immunization as shown, beginning at day 0, and the numbers of infectious bites, 
are shown as red boxes. The day of CHMI is shown as blue boxes. Nine of 10 subjects were protected
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were required for protection [19–21]. PfRAS administered 
by mosquito bite is not being developed as a human vac-
cine, although considerable progress is being made using 
radiation-attenuated, aseptic, purified, cryopreserved 
sporozoites (PfSPZ Vaccine) administered by direct venous 
inoculation using a syringe [16, 17]. The study reported 
here was undertaken to further elucidate the mechanisms 
and antigenic targets of protective immunity induced by 
immunization with PfRAS by mosquito bite through the 
collection of sera and PBMCs from protected and non-
protected subjects. The results of several studies using the 
sera and PBMCs from this clinical study have been pub-
lished [35–37, 50, 51]. Here, the method of immunization, 
safety and tolerability, and antibody responses to selected 
P. falciparum antigens are reported.
In earlier PfRAS studies, including a few subjects that 
received Plasmodium vivax RAS, immunization was 
safe and well tolerated, highlighting as common events 
mild discomfort during mosquito feeding, erythaema, 
erythaematous papules, focal and sometimes more gen-
eralized local swelling, mild headaches and malaise that 
spontaneously resolved within 24  h [15]. In the current 
study, PfRAS immunization was also generally well toler-
ated, although two subjects experienced significant large 
local reactions of the forearm (swelling from elbow to 
wrist) and two other subjects experienced sudden onset 
systemic symptoms 16 h after immunization. Due to con-
cern regarding the potential for systemic allergic reactions 
if immunizations were to continue, both cases of large 
local reaction led to exclusion from further participation. 
Other than the two large local reactions, local AEs were 
consistent with prior reports and with reactions to mos-
quito bites in nature: erythaema, papules, swelling, and 
induration. Large local reactions have only rarely been 
Table 3 Summary of immunizations in this study (1999–2002) and the previous study (1989–1999)
Part A summaries (median, range) of the immunizations in the 1999–2002 and 1989–1999 [15] studies were compared using the Mann–Whitney U test, where 
significance is P ≤ 0.05; these parameters were significantly different between each study except the median time between each immunization
Part B summaries of protected and non-protected subjects in each study were combined and compared using the Mann–Whitney U test, where significance is 
P ≤ 0.05; only the interval before CHMI (days between last immunization and CHMI) was significant
a Derived from combining the two groups shown in Table 2
b Gland score as defined in “Methods” section, salivary infection rates were defined as gland scores: 1–10 sporozoites = gland score 1; 11–100 sporozoites = gland 
score 2; 101–1000 sporozoites = gland score 3; and >1000 = gland score 4
A Individual study data P value
1999–2002a 1989–1999
Median Range Median Range
Infected bites in the first immunization 224 138–334 148 130–210 0.0065
Total infected bites 1247 1005–1561 1092 1001–1163 0.0288
Median infected bites per immunization 214 175–260 125 109–210 0.0006
Number of immunizations 6 5–6 8.5 5–10 0.0014
Duration of immunizations (days) 206 175–239 241.5 99–547 0.0450
Median immunization interval (days) 43.5 35–48 31 23–77 0.2401
Median Interval before CHMI (days) 35 15–42 16 14–71 0.0434
Median gland grade scorea during immunization 3.5 3.2–3.9 3.2 3.0–3.7 0.0045
Median gland grade score during CHMI 2.7 2.4–3.2 3.2 2.8–3.4 0.0017
B Combined data (1989–2002) P value
Protected Non‑protected
Median Range Median Range
Infected bites in the first immunization 159 130–334 148 133–250 0.4829
Total infected bites 1110 1001–1561 61170 1008–1366 0.7728
Median infected bites per immunization 138 109–260 125 112–228 0.2652
Number of immunizations 8 5–10 6 5–9 0.2293
Duration of immunizations (days) 221 99–547 196 180–455 0.3639
Median immunization interval (days) 38.5 23–77 43.5 36–57 0.3630
Median Interval before CHMI (days) 20 14–42 36 25–71 0.0088
Median gland grade scoreb during immunization 3.3 3.0–3.9 3.5 3.0-3.8 0.2155
Median gland grade score during CHMI 3.1 2.4–3.4 2.7 2.4–3.2 0.0629
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reported following mosquito bites in nature [52] and may 
relate to the very large antigenic load associated with hun-
dreds of mosquito bites occurring simultaneously during 
immunization sessions. Because one of the two subjects 
experiencing a large local reaction to the mosquito bites 
was mock-immunized and that reaction was very similar 
to that of the true-immunized subject, it is probable that 
sporozoites themselves did not contribute to the large 
local reaction in the true-immunized subject.
Systemic AEs occurred at a lower rate than local AEs 
and were generally mild, consisting of headache, myal-
gia, nausea, and low-grade fever. However, two subjects 
experienced the abrupt onset of symptoms 16  h after 
immunization and these reactions were consistent with 
serum sickness-like reactions that can occur when pre-
formed antibodies react with administered antigens. One 
of the subjects was withdrawn, and the second received 
an additional immunization without recurrence of sys-
temic AEs. Both were true-immunized subjects, preclud-
ing differentiation of the effects of mosquito saliva from 
the effects of sporozoites.
When true- and mock-immunized research subjects 
were compared overall, there were no qualitative differ-
ences in the numbers of local AEs for each subject. More 
Fig. 7 Comparison of the interval (in days) from last immunization to CHMI for individuals immunized in 1999–2002 (this study) and 1989–1999. 
The relationship between total number of mosquito bites and days after CHMI and protective efficacy is shown for the 1999–2002 study (a) and 
the 1989–1999 studies [15] (b). The threshold number that induced up to 93 % protection in previous studies [15] is indicated by a dotted vertical 
line. Protected subjects are shown as blue dots, and non-protected subjects are shown as red dots. For both studies, subjects were predominantly 
protected when CHMI was less than 28 days, and were predominantly not protected more than 28 days, after the last immunization, shown by the 
horizontal dotted line. However, these differences were not statistically significantly different in either study using the Mann–Whitney U test.  
c Protected and non-protected subjects in the 1999–2002 and 1989–1999 studies are combined, and grouped according to time of CHMI in days 
after the final immunization; the median time in days is shown for each group as colour-coded horizontal lines, and the difference was significant 
(P = 0.001) using Mann–Whitney U test
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systemic AEs were recorded in the true-immunized 
group than in the mock-immunized group, but the num-
ber of systemic AEs was small in both groups, preclud-
ing meaningful comparison. Thus, these data support the 
hypothesis that the reactogenicity and systemic AEs seen 
following immunization with PfRAS via mosquito bite 
result primarily from the complex mixture of mosquito 
antigens in the saliva [52, 53]. This is consistent with the 
minimal reactogenicity reported when aseptic, purified, 
cryopreserved sporozoites have been administered intra-
dermally, subcutaneously or intravenously in the absence 
of mosquito saliva [16, 17, 54–61].
PfRAS efficacy appears to be characterized by a thresh-
old effect greater than 1000 infectious bites induced 
protection in 13/14 (93 %) subjects in the early studies, 
while protection was only 33  % (five out of 15) in sub-
jects immunized with fewer than 1000 infectious bites, 
although there were subjects protected after receiving as 
few as 400 irradiated infectious bites [15, 62]. A similar 
threshold has been identified in studies of PfSPZ vaccine 
[16]. In this study, only five/ten (50  %) subjects, all of 
whom received at least 1000 infectious bites, were pro-
tected against CHMI. This was an unexpected decrease 
in sterile protection from the results obtained previously 
[15]. Several hypotheses can be advanced to explain this 
difference. Firstly, the observed variability in sterile pro-
tection may be due to host genetics, biting behaviour of 
mosquitoes, salivary gland sporozoite counts, or other 
host-vector-parasite interactions. The efficacy induced 
by 1000 infectious PfRAS bites may range from a likely 
high-end estimate of  >90  % to a low-end estimate of 
50 % depending on these factors, particularly when the 
total sporozoite dose is near the protective threshold. 
Differences in the immunization and CHMI procedures 
may also have played a role, such as the longer interval 
between the final immunization and CHMI in these sub-
jects compared to previous studies (Fig. 7). The efficacy 
induced by PfRAS may have declined beyond 3  weeks 
post immunization, due to a waning immune response. 
As a third hypothesis to explain the reduced protection 
seen in this study, the leukapheresis procedure used to 
collect PBMCs prior to CHMI in this study may have 
depleted the immune response.
The protection induced by PfRAS also appears to be 
durable. In the prior study, six protected subjects under-
went additional CHMI 23–24 weeks after the last exposure 
to sporozoites, and five out of six were protected, indicat-
ing that once established, protection is durable. The same 
conclusion was reached in a study of PfSPZ Vaccine, where 
once a subject was protected using an adequate dose of 
sporozoites, protection against a second CHMI lasted at 
least 59  weeks [65]. In the current study, one non-pro-
tected subject underwent a second CHMI, but received 
additional immunizations between the first and second 
CHMI, and was protected after the second CHMI.
It is noteworthy that the non-protected subjects in 
this trial all showed a delay to parasitaemia. This delay 
was interpreted to indicate partial immunity—decreased 
liver stage parasite burden leading to the release of fewer 
parasites into the blood and therefore later onset of par-
asitemia. This inference rests on the assumption that 
growth rates in the blood were similar for the non-pro-
tected true-immunized research subjects and the non-
immunized infectivity controls.
As previously reported [10, 63, 64], PfRAS-immunized 
subjects developed antibody responses to whole P. fal-
ciparum sporozoites and P. falciparum CSP. Although 
antibody responses to other pre-erythrocytic antigens 
were low or absent, cellular assays have demonstrated 
the presence of T cell responses to antigens expressed in 
Fig. 8 IFA and ELISA CSP responses. IFA (a) and ELISA (b) titres meas-
ured at pre-immunization (Pre) and 2 weeks after each immunization. 
Blue circles represent protected subjects, green circles represent non-
protected subjects, and the red line represents the geometric mean of 
each group. There was no significant difference between protected 
and non-protected subjects
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sporozoites and liver stages (PfCSP, PfTRAP, PfEXP1), 
and in one study to a liver-(PfLSA1) and blood-stage 
antigens [14]. Sera from these PfRAS-immunized sub-
jects have been used to screen protein microarrays to 
identify novel antigens recognized by these subjects as 
potentially contributing to protective efficacy [36, 50], as 
well as PBMC in cell-free transcription translation strate-
gies [51]. Recently, sera and PBMC from these subjects 
were used to identify and characterize a panel of 27 novel 
P. falciparum antigens that provides evidence to further 
evaluate these antigens as candidate vaccines [35].
While PfRAS administered by infectious mosquito 
bites is not being further developed as a vaccine, recently 
administration of radiation-attenuated (metabolically 
active, non-replicating), aseptic, purified, cryopreserved 
P. falciparum sporozoites by intravenous inoculation has 
achieved 100  % efficacy in human trials [16]. The dose 
required (1.35 × 105 sporozoites in five doses) was consist-
ent with  >1000 PfRAS mosquito bites that elicited up to 
93 % protection, and protection last for at least 59 weeks 
after CHMI as tested in a small number of immunized 
subjects [65]. Thus, partial efficacy in mice with radiation-
attenuated Plasmodium berghei first reported in 1967 [2], 
has now led 50 years later, to a vaccine shown to be highly 
effective in clinical trials against P. falciparum.
Conclusions
These studies extend the results of previous studies and 
show that irradiated PfSPZ administered by the bite 
of  >1000 infected mosquitoes induce protective immu-
nity. However, the level of protective immunity after 
this regimen of immunization may not be as consist-
ently high as previously reported, and may be influenced 
by variability in host genetics, mosquito biting, or trial 
procedures, such as the use of leukapheresis or longer 
intervals between immunization and CHMI. Given that 
higher doses of sporozoites appear to induce more robust 
immunity, these effects may be most apparent when the 
total number of sporozoites administered is near the pro-
tective threshold.
Additional files
Additional file 1. Flow diagram of subjects immunized after the first 
CHMI. Four subjects who received CHMI (three from 1999-2000 and one 
from 2001-2002) and one subject who did not receive CHMI, received 
immunization 7. Two of these received immunization 8, and two subjects 
received immunizations 8-11. One subject (number 20) received immu-
nization 12 (completing six immunizations after the first CHMI) and then 
received a second CHMI, and then received one more immunization 
(number 13).
Additional file 2. Adverse events experienced by two subjects who 
received more than six immunizations.
Additional file 3. Days between leukapheresis and CHMI for protected 
and non-protected subjects.
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also holds a Department of Defense/Department of the Navy Federal-wide 
Assurance for human subject protections. All key personnel were certified as 
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having completed mandatory human research ethics education curricula and 
training under the direction of the WRAIR Institutional Research Board or the 
NMRC Office of Research Administration (ORA) and Human Subjects Protec-
tions Program (HSPP). All potential study subjects provided written, informed 
consent before screening and enrolment and had to pass an assessment of 
understanding.
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